Session » Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes
- 9:00AM-11:00AM
-
Abstract Number: 424
A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index
- 9:00AM-11:00AM
-
Abstract Number: 421
An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 428
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
- 9:00AM-11:00AM
-
Abstract Number: 420
Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials
- 9:00AM-11:00AM
-
Abstract Number: 430
Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients
- 9:00AM-11:00AM
-
Abstract Number: 433
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
- 9:00AM-11:00AM
-
Abstract Number: 429
Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results
- 9:00AM-11:00AM
-
Abstract Number: 417
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 427
Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD
- 9:00AM-11:00AM
-
Abstract Number: 444
Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration
- 9:00AM-11:00AM
-
Abstract Number: 425
Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
- 9:00AM-11:00AM
-
Abstract Number: 440
Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome
- 9:00AM-11:00AM
-
Abstract Number: 432
Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry
- 9:00AM-11:00AM
-
Abstract Number: 416
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
- 9:00AM-11:00AM
-
Abstract Number: 439
Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection
- 9:00AM-11:00AM
-
Abstract Number: 437
Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?
- 9:00AM-11:00AM
-
Abstract Number: 434
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
- 9:00AM-11:00AM
-
Abstract Number: 438
Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?
- 9:00AM-11:00AM
-
Abstract Number: 442
Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care
- 9:00AM-11:00AM
-
Abstract Number: 441
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
- 9:00AM-11:00AM
-
Abstract Number: 423
Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration
- 9:00AM-11:00AM
-
Abstract Number: 413
Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort
- 9:00AM-11:00AM
-
Abstract Number: 436
Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 431
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 419
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
- 9:00AM-11:00AM
-
Abstract Number: 422
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 426
Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
- 9:00AM-11:00AM
-
Abstract Number: 414
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
- 9:00AM-11:00AM
-
Abstract Number: 435
Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
- 9:00AM-11:00AM
-
Abstract Number: 443
Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 415
Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials